NorthX Biologics Secures Significant Growth Investment from Signet Healthcare Partners

Audio By Carbonatix

STOCKHOLM--(BUSINESS WIRE)--May 20, 2025--

NorthX Biologics, a leading Nordic biopharmaceutical Contract, Development and Manufacturing Organization (CDMO), is pleased to announce a significant growth investment from Signet Healthcare Partners (Signet), a U.S.-based healthcare private equity firm with deep expertise in pharmaceutical services. This strategic partnership will enable NorthX Biologics to accelerate its expansion plans, including enhancing facilities, broadening service lines, and extending U.S. commercial reach.

NorthX Biologics provides a wide range of complex biologics manufacturing services, including recombinant proteins, viral vaccines and cell therapies. It serves a global customer base of biopharmaceutical and biotech companies, from early development through commercial GMP manufacturing.

The investment was made through a new issue of shares. Following the transaction, James Gale, Managing Director at Signet Healthcare Partners, will join the NorthX Biologics Board of Directors.

“We are delighted to welcome Signet Healthcare Partners as a shareholder. With their significant experience in pharma services, they are an excellent complement to NorthX Biologics and are well positioned to support our journey,” said Janet Hoogstraate, Chief Executive Officer of NorthX Biologics.

“With Signet Healthcare Partners, we gain another strong owner who brings extensive experience in developing fast-growing biopharmaceutical companies. I look forward to welcoming James to the board and working together with Signet to continue the global expansion of NorthX Biologics,” added Thomas Eldered, Chairman of NorthX Biologics and Flerie.

“We are excited to invest in NorthX Biologics to support its ambitious growth strategy. NorthX Biologics’ differentiated capabilities across microbial and mammalian manufacturing systems, nucleic acids, advanced therapies and aseptic fill-finish are a strong match with the evolving needs of the global biopharma market. Together with Flerie, as a significant shareholder in NorthX Biologics, we look forward to helping accelerate NorthX Biologics commercial strategy while supporting its broader global vision,” said James Gale, Managing Director at Signet Healthcare Partners.

Flerie remains the majority shareholder following the transaction. Terms were not disclosed. Setterwalls served as legal advisor to NorthX Biologics. Advokatfirman Delphi and Sheppard, Mullin, Richter & Hampton served as legal advisors to Signet.

About NorthX Biologics

NorthX Biologics is a CDMO and Innovation Hub in Advanced Biologics, with +30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cells and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide and in 2021 was recognized as a national innovation hub for advanced therapeutics and vaccines. NorthX Biologics has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies.

For more information see www.nxbio.com.

About Flerie

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

About Signet Healthcare Partners

Signet Healthcare Partners is a leading provider of growth capital to innovative healthcare companies, with a focus on the pharmaceutical and medical device sectors. With over 25 years of experience, Signet has raised cumulative capital commitments exceeding $600 million and invested in over 60 companies. The firm works closely with its portfolio companies to drive value and accelerate growth. For more information, visit www.signethealthcarepartners.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250520072368/en/

CONTACT: Media inquiries

CEO Janet Hoogstraate:

[email protected]

KEYWORD: SWEDEN

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH MEDICAL DEVICES

SOURCE: NorthX Biologics

Copyright Business Wire 2025.

PUB: 05/20/2025 08:30 AM/DISC: 05/20/2025 08:29 AM

http://www.businesswire.com/news/home/20250520072368/en